Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function

• Type of Material: Article
• Authors: Fang Hua, Emory University; X Wang, Emory University; TWW Pace, Emory University; H Wu, Emory University; Andrew H Miller, Emory University
• Language: English
• Date: 2005-05
• Publisher: Springer Nature [academic journals on nature.com]: Hybrid Journals
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2005 Nature Publishing Group
• Final Published Version (URL): http://www.nature.com/mp/journal/v10/n5/full/4001644a.html
• Title of Journal or Parent Work: Molecular Psychiatry
• ISSN: 1359-4184
• Volume: 10
• Issue: 5
• Start Page: 426
• End Page: 428
• Grant/Funding Information: National Institute of Mental Health : NIMH; This work was supported in part by grants from the National Institute of Mental Health (MH-067041) and the Emory University Research Committee Award.
• Research Categories: Psychology, Behavioral

Abstract

Sir—Celecoxib is a widely used nonsteroidal anti-inflammatory agent that acts through selective inhibition of COX-2. Here we demonstrate that celecoxib also significantly increases nuclear localization of the glucocorticoid receptor (GR), increases GR binding to its DNA responsive element and enhances GR-mediated gene transcription in association with inhibition of p38 MAP kinase. These results expand the intracellular targets of COX-2 inhibitors while widening their potential clinical application to multiple disorders associated with impaired GR function including major depression.